About: Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 01 February 1995

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована в лютому 1995 (uk) im Februar 1995 veröffentlichter wissenschaftlicher Artikel (de) artículu científicu espublizáu en febreru de 1995 (ast) artikull shkencor i botuar më 01 shkurt 1995 (sq) scientific article published on 01 February 1995 (en)
publication date	wds:Q72516643-593FE976-E67A-4D48-A0C5-9C50DA4B84C9
publication date	1995-02-01 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q72516643-93376D56-0A02-4C87-8020-C166B1B7D213
language of work or name	English
author name string	wds:Q72516643-04C22CE4-B57B-46D1-9B6E-060F5CCE191C wds:Q72516643-26906424-EECD-406E-BE49-ADA530F83A39 wds:Q72516643-35CEA73E-19FE-46CC-8C24-90E702666DAA wds:Q72516643-67D3009C-0A24-483F-9DA5-25F4493CD71F wds:Q72516643-712901B2-69F0-4AFD-99B6-4C82CBA630F3 wds:Q72516643-7497EC49-5468-403C-81FB-7A0BF9BB1E99 wds:Q72516643-751F61CE-7C6A-49E4-B2AE-EEF3BF1B88C8 wds:Q72516643-8B62FA65-D235-4630-BCE2-329A4B39EAEF wds:Q72516643-B979EB32-F665-4BF1-9A13-33B02175673F wds:Q72516643-CC35D7A0-00E4-4933-9DA6-978FEAF7C5C5
author name string	P Fumoleau P Kerbrat B Chevallier I Krakowski N Azli M Van Glabbeke H Roche V Dieras M A Lentz M Bayssas
rdfs:label	Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer (en) Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer (nl) Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer (sq)
skos:prefLabel	Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer (en) Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer (nl) Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer (sq)
name	Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer (en) Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer (nl) Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer (sq)
title	wds:Q72516643-D99CB647-5FDC-4F77-868E-C0B87353C4D4
title	Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer (en)
page(s)	wds:Q72516643-25464F1D-BDA3-4C8C-A726-77E259F686FA
page(s)	314-322
instance of	wds:Q72516643-CA0B6145-60B1-4BAF-8DA0-805FB092D86F
instance of	scholarly article
main subject	wds:Q72516643-0E58D6C3-A513-4064-8C9C-E5981E8D34AC wds:Q72516643-74540677-BBDA-4231-ABC7-CD6C3C8D808D wds:Q72516643-9AD6631A-1EAA-4FD0-87D0-FEC4C555D1B2
main subject	wd:Q420436 breast cancer phase II clinical trial
PubMed ID	wds:Q72516643-DD826047-D1D0-4F00-BACB-29AEAAC7BF71
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/7844592
PubMed ID	7844592
published in	wds:Q72516643-BB5B7BA6-F462-4490-A060-6228E5CAB733
published in	Journal of Clinical Oncology
issue	wds:Q72516643-6AF404C9-C5BF-40BF-9050-66CA49D99BBA
volume	wds:Q72516643-F3D8CE9F-5DF2-4844-8F1E-D4FD348A7EE8
issue	2
volume	13
DOI	wds:Q72516643-069F64A5-3797-4CEE-AB8B-E9FB28D7CA6D
DOI	http://dx.doi.org/10.1200/JCO.1995.13.2.314
DOI	10.1200/JCO.1995.13.2.314
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q72516643
is cites work of	Phase I study on docetaxel and ifosfamide in patients with advanced solid tumours Efficacy and safety of docetaxel (Taxotere) in heavily pretreated advanced breast cancer patients: the French compassionate use programme experience Docetaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of metastatic breast cancer Advanced breast cancer: investigational role of gemcitabine Monthly docetaxel and weekly gemcitabine in metastatic breast cancer: a phase II trial Phase II trial of docetaxel (Taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: the Eastern Cooperative Oncology Group (ECOG) results of protocol E1293. Delayed emotional recovery after taxane-based chemotherapy Pharmacoethnicity of docetaxel-induced severe neutropenia: integrated analysis of published phase II and III trials. A new decision model for cost-utility comparisons of chemotherapy in recurrent metastatic breast cancer Cisplatin-epirubicin-paclitaxel weekly administration with G-CSF support in advanced breast cancer. A Southern Italy Cooperative Oncology Group (SICOG) phase II study Sequential docetaxel as adjuvant chemotherapy for node-positive or/and T3 or T4 breast cancer: clinical outcome (Mansoura University). The taxoids. Comparative clinical pharmacology and therapeutic potential A phase I and pharmacokinetic study of the combination of capecitabine and docetaxel in patients with advanced solid tumours Peripheral neuropathy induced by combination chemotherapy of docetaxel and cisplatin Docetaxel: an update of its use in advanced breast cancer Phase II trial of docetaxel (Taxotere) in patients with metastatic melanoma previously untreated with cytotoxic chemotherapy Simple and sensitive high-performance liquid chromatography method for the determination of docetaxel in human plasma or urine Docetaxel-cisplatin combination (DC) chemotherapy in patients with anthracycline-resistant advanced breast cancer Weekly paclitaxel-cisplatin administration with G-CSF support in advanced breast cancer. A phase II study Neoadjuvant docetaxel for operable breast cancer induces a high pathological response and breast-conservation rate Prevention of chemotherapy-induced alopecia using an effective scalp cooling system A phase II study in advanced breast cancer: ZD1694 ('Tomudex') a novel direct and specific thymidylate synthase inhibitor Incidence of anaemia in breast cancer patients receiving adjuvant chemotherapy Effectiveness of cold cap in the prevention of docetaxel-induced alopecia Dose-finding study of docetaxel and doxorubicin in first-line treatment of patients with metastatic breast cancer Matched case-control phase 2 study to evaluate the use of a frozen sock to prevent docetaxel-induced onycholysis and cutaneous toxicity of the foot Docetaxel-loaded pluronic p123 polymeric micelles: in vitro and in vivo evaluation A phase I study of docetaxel and 5-fluorouracil in patients with advanced solid malignancies Docetaxel: response in patients who have received at least two prior chemotherapy regimens for metastatic breast cancer Results of chest wall reirradiation using pulsed-dose-rate (PDR) brachytherapy molds for breast cancer local recurrences Phase I dose-finding and pharmacokinetic study of docetaxel and vinorelbine as first-line chemotherapy for metastatic breast cancer The role of oncogenes in drug resistance Chemotherapy-induced complete regression of choroidal metastases and subsequent isolated leptomeningeal carcinomatosis in advanced breast cancer: a case report and literature review Vinorelbine combined with paclitaxel infused over 96 hours (VI-TA-96) for patients with metastatic breast carcinoma Key issues in the treatment of advanced breast cancer. Expectations and outcomes

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 194 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software